Lars Fruergaard Jørgensen, Novo Nordisk CEO (Nanna Navntoft/Bloomberg via Getty Images)
November 1, 2024 11:28 AM EDT
R&D

No­vo Nordisk claims late-stage MASH vic­to­ry, con­tin­u­ing GLP-1's ex­pan­sion

Max Bayer

Pharma Reporter

A day af­ter Madri­gal Phar­ma­ceu­ti­cals im­pressed in­vestors, No­vo Nordisk is look­ing to steal the spot­light.

The Dan­ish drug­mak­er re­port­ed Fri­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times